Iambic Therapeutics, Inc. (NASDAQ:IAM – Get Free Report) dropped 7.1% during trading on Thursday. The stock traded as low as $13.56 and last traded at $13.71. Approximately 116,557 shares were traded during mid-day trading, a decline of 83% from the average session volume of 673,820 shares. The stock had previously closed at $14.76.
Analysts Set New Price Targets
A number of research analysts have recently commented on IAM shares. Jefferies Financial Group started coverage on shares of Iambic Therapeutics in a research note on Tuesday, November 10th. They set a “buy” rating and a $35.00 price objective for the company. Wall Street Zen raised Iambic Therapeutics to a “hold” rating in a report on Saturday, November 7th. Zacks Research started coverage on shares of Iambic Therapeutics in a report on Tuesday, November 10th. They issued a “hold” rating on the stock. Citigroup initiated coverage on shares of Iambic Therapeutics in a research report on Monday, November 9th. They issued a “buy” rating and a $22.00 target price for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of Iambic Therapeutics in a research note on Monday, November 9th. They issued an “overweight” rating and a $22.00 price target for the company. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $27.25.
Iambic Therapeutics Stock Down 4.7%
Insider Activity at Iambic Therapeutics
In related news, Director Evan Lockwood Rachlin purchased 718,750 shares of Iambic Therapeutics stock in a transaction that occurred on Friday, October 16th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $11,500,000.00. Following the transaction, the director directly owned 2,588,248 shares in the company, valued at approximately $41,411,968. This represents a 38.45% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 22.90% of the company’s stock.
About Iambic Therapeutics
Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.
Featured Articles
- Five stocks we like better than Iambic Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
